David Coy Ross - Jun 15, 2025 Form 3 Insider Report for Health Catalyst, Inc. (HCAT)

Role
Chief Tech & Product Officer
Signature
/s/ Benjamin Landry, as Attorney-in-Fact
Stock symbol
HCAT
Transactions as of
Jun 15, 2025
Transactions value $
$0
Form type
3
Date filed
6/25/2025, 04:49 PM
Next filing
Sep 4, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ross David Coy Chief Tech & Product Officer C/O HEALTH CATALYST, INC., 10897 SOUTH RIVER FRONT PARKWAY #300, SOUTH JORDAN /s/ Benjamin Landry, as Attorney-in-Fact 2025-06-25 0002074748

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding HCAT Common Stock 625 Jun 15, 2025 Direct F1
holding HCAT Common Stock 1.13K Jun 15, 2025 Direct F2
holding HCAT Common Stock 1.88K Jun 15, 2025 Direct F3
holding HCAT Common Stock 10.9K Jun 15, 2025 Direct F2
holding HCAT Common Stock 21.9K Jun 15, 2025 Direct F4
holding HCAT Common Stock 90K Jun 15, 2025 Direct F5
holding HCAT Common Stock 81.1K Jun 15, 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents an award of restricted stock units ("RSUs") granted pursuant to the Issuer's 2019 Stock Option and Incentive Plan (the "2019 Plan"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the terms of the 2019 Plan, 25% of the RSUs vested on September 1, 2022 and the remaining 75% of the RSUs vested or will vest in 12 equal quarterly installments.
F2 Represents an award of RSUs granted pursuant to the 2019 Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the terms of the 2019 Plan, 25% of the RSUs vested on December 1, 2022 and the remaining 75% of the RSUs vested or will vest in 12 equal quarterly installments.
F3 Represents an award of RSUs granted pursuant to the 2019 Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the terms of the 2019 Plan, 25% of the RSUs vested on September 1, 2023 and the remaining 75% of the RSUs vested or will vest in 12 equal quarterly installments.
F4 Represents an award of RSUs granted pursuant to the 2019 Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the terms of the 2019 Plan, 25% of the RSUs vested on December 1, 2024 and the remaining 75% of the RSUs vested or will vest in 12 equal quarterly installments.
F5 Represents an award of RSUs granted pursuant to the 2019 Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the terms of the 2019 Plan, 33.33% of the RSUs will vest on December 1, 2025 and the remaining 66.67% of the RSUs will vest in 8 equal quarterly installments.